
CAS 1638250-96-0
:Formula:C19H17N7O3
InChI:InChI=1S/C19H17N7O3/c1-24-17-16(18(28)25(2)19(24)29)26(11-20-17)10-15(27)21-14-9-8-13(22-23-14)12-6-4-3-5-7-12/h3-9,11H,10H2,1-2H3,(H,21,23,27)
InChI key:QTRXIFVSTWXRJJ-UHFFFAOYSA-N
SMILES:CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)NC3=NN=C(C=C3)C4=CC=CC=C4
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 8 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
2-(1,3-Dimethyl-2,6-Dioxo-1,2,3,6-Tetrahydro-7H-Purin-7-Yl)-N-(6-Phenylpyridazin-3-Yl)Acetamide
CAS:2-(1,3-Dimethyl-2,6-Dioxo-1,2,3,6-Tetrahydro-7H-Purin-7-Yl)-N-(6-Phenylpyridazin-3-Yl)AcetamideFormula:C19H17N7O3Purity:98%Molecular weight:391.387H-PURINE-7-ACETAMIDE, 1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-N-(6-PHENYL-3-PYRIDAZINYL)-
CAS:Formula:C19H17N7O3Purity:98%Color and Shape:SolidMolecular weight:391.3834Ref: IN-DA001UF2
1gTo inquire1mg49.00€5mg60.00€10mg79.00€25mg122.00€50mg202.00€100mg291.00€250mg554.00€ETC-159
CAS:2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamideFormula:C19H17N7O3Purity:98%Molecular weight:391.38ETC-159
CAS:ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor. It inhibits β-catenin reporter activity with an IC50 of 2.9 nM.Formula:C19H17N7O3Purity:96.87% - 99.30%Color and Shape:SolidMolecular weight:391.387H-PURINE-7-ACETAMIDE, 1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-N-(6-PHENYL-3-PYRIDAZINYL)-
CAS:Purity:98%Molecular weight:391.39099121,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-N-(6-phenyl-3-pyridazinyl)-7H-purine-7-acetamide
CAS:Controlled ProductApplications 1,2,3,6-Tetrahydro-1,3-dimethyl-2,6-dioxo-N-(6-phenyl-3-pyridazinyl)-7H-purine-7-acetamide is a novel potent PORCN inhibitor that blocks the secretion and activity of all Wnts.
References Madan, B., et al.: Oncogene, 35, 2197-2207 (2016);Formula:C19H17N7O3Color and Shape:NeatMolecular weight:391.383ETC-159
CAS:Controlled ProductETC-159 is a monoclonal antibody that binds to and inhibits the function of β-catenin. It is an orally administered drug that has been shown to be effective for the treatment of solid tumours, such as colorectal cancer. ETC-159 blocks the cell signaling pathways mediated by β-catenin, which may lead to tumor suppression. This drug also has the ability to inhibit TNF-α and suppressor genes in cancer cells, which are involved in tumor growth. The chemical structure of this molecule includes a pan-PI3K inhibitor with a potential application in inhibiting cancers that are not responsive to conventional therapy.Formula:C19H17N7O3Purity:Min. 95%Molecular weight:391.38 g/mol






